6533b838fe1ef96bd12a4f68
RESEARCH PRODUCT
Halogen-containing BODIPY derivatives for photodynamic therapy
Katherine ChulviKatherine ChulviRamón Martínez-máñezSalvador GilSalvador GilAna M. CosteroAna M. CosteroRaúl GotorRaúl GotorRafael Ballesteros-cilleroRafael Ballesteros-cilleroFélix SancenónLuis E. OchandoLuis E. OchandoMónica Gorbesubject
Aqueous solutionbiologySinglet oxygenProcess Chemistry and TechnologyGeneral Chemical Engineeringmedicine.medical_treatmentPhotodynamic therapy02 engineering and technology010402 general chemistry021001 nanoscience & nanotechnologybiology.organism_classificationPhotochemistry01 natural sciences0104 chemical sciencesHeLachemistry.chemical_compoundHaCaTchemistryHalogenmedicineBODIPY0210 nano-technologyVisible spectrumdescription
Abstract Two iodinated (1 and 2) and two brominated (3 and 4) BODIPY-based photosensitizers are prepared and characterized using slightly modified synthetic procedures previously described. 1–4 present intense absorption bands in the 510–540 nm interval and very weak emissions due to the presence of halogen atoms in their structure. Irradiation of aqueous solutions of 1–4 with visible light (wavelength > 475 nm) induce the generation of singlet oxygen with quantum yields of ca. 0.62–0.66 for the photosensitizers containing iodine atoms (1 and 2) and of ca. 0.16–0.21 for the brominated counterparts (3 and 4). In vitro studies carried out with HeLa, SCC-13 and HaCaT cell lines and the four photosensitizers show marked reductions in cell viability with lower IC50 values for the iodinated derivatives (in the 0.82–2.51 range) than those found for the brominated compounds (in the 0.91–8.26 range) suggesting that these compounds could be used in photodynamic therapy protocols. Subcellular localization studies carried out using confocal microscopy show that photosensitizers accumulated in the endoplasmic reticulum.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-01 | Dyes and Pigments |